The Technion and Pfizer, one of the world’s leading biopharmaceutical companies, recently signed a collaboration framework agreement to identify opportunities for collaboration and present scientific advances at the interface between artificial intelligence and drug development. The agreement was closed during a visit from a Pfizer delegation led by Chairman and CEO Dr. Albert Bourla and included Dr. Mikael Dolsten, Chief Scientific Officer and President of Worldwide Research, Development and Medicine; Lidia Fonseca, Executive Vice President and Director of Technology and Digital; and other senior executives.
The framework agreement is in line with the Technion’s ambition to advance technological and medical developments by identifying new technologies and various digital tools with potential industrial applications. Technion President Professor Uri Sivan stated, “Human health is one of the great challenges facing humanity in the 21st century. Like other global challenges, current scientific and technological advances require multidisciplinary research and close cooperation between academia and industry. We recently launched Tech.AI, the Technion’s AI hub, to serve as the Technion’s main platform and provide faculty and students across all Technion units with the best possible access to the cutting edge of AI research and application. Cooperation with industry, where the big challenges lie, is vital for a company of this type, and I therefore look forward to Pfizer’s potential contributions to this mission.”
Pfizer, a multinational pharmaceutical company with 170 years of experience developing innovative medicines and vaccines, has had a tremendous impact on global health in recent years by developing, with BioNTech, vaccines that help protect against the COVID-19 virus. In addition to its internal drug discovery efforts, Pfizer regularly collaborates with the biotechnology industry and academia to identify research and technologies that could lead to scientific breakthroughs.
The collaboration between the Technion and Pfizer is expected to accelerate scientific advances. By combining the Technion’s expertise in AI and the pharmaceutical industry’s experience in drug discovery, the two organizations hope to develop new technologies and treatments that could have a positive impact on global health.
Do you want to know more about Israeli technology? Read our other articles to learn more about the latest developments in the field.